Citations

Clear

410 citation(s) found for "Shu, Yu".

Abstract 1069: Mutant p53 disrupts the role of ShcA in balancing the Smad-dependent and -independent signaling activity of TGF-β
Lin, Shu, Yu, Lan , Karia, Bijal, Copland, John A. , Mu, Xiaoxin , Sun, Lu‐Zhe , Yang, Junhua , Liu, Zhao , Bishop, Alexander J.R. , Jackson, James Grey , Lozano, Guillermina , Sun, Beicheng

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 1069-1069

10.1158/1538-7445.am2012-1069 Get It

Abstract Biomarkers are lacking for identifying the switch of transforming growth factor-beta (TGF-β) from tumor-suppressing to tumor-promoting. Mutated p53 (mp53) has been suggested to switch TGF-β to a tumor promoter. However, we found that mp53 does not always promote the oncogenic role of TGF-β. Here, we show that endogenous mp53 knockdown enhanced cell migration and phosphorylation of ERK in DU145 prostate cancer cells. Further, ectopic expression of mp53 in p53-null PC-3 prostate cancer cells enhanced Smad-dependent signaling, but inhibited TGF-β-induced cell migration by downregulating activated ERK. Reactivation of ERK by the expression of its activator, MEK-1, restored TGF-β-induced cell migration. Since TGF-β is known to activate MAPK/ERK pathway through direct phosphorylation of adaptor protein ShcA and MAPK/ERK signaling is pivotal to tumor progression, we investigated whether ShcA contributed to mp53-induced ERK inhibition and the conversion of TGF-β's role during carcinogenesis. We found that mp53 expression led to decrease of phosphorylated p52ShcA/ERK levels and increase of phosphorylated Smad levels in a panel of mp53-expressing cancer cell lines, and in mammary glands and tumors from mp53 knock-in mice. By manipulating ShcA levels to regulate ERK and Smad signaling in human untransformed and cancer cell lines, we show that TGF-β's role in regulating anchorage-dependent and -independent growth, and migration, can be shifted between growth suppression and migration promotion. Thus, our results, for the first time, suggest that mp53 disrupts ShcA's role in balancing Smad-dependent and -independent signaling activity of TGF-β and that ShcA/ERK signaling is a major pathway regulating the tumor-promoting activity of TGF-β. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1069. doi:1538-7445.AM2012-1069
Abstract 1900: Age at last birth and endometrial cancer risk: Pooled analysis in the Epidemiology of Endometrial Cancer Consortium
Karageorgi, Stalo , Deming, Sandra L., Anderson, Kristin E. , Brinton, Louise A. , Chen, Chu , Horn‐Ross, Pamela L., Lissowska, Jolanta , Lurie, Galina, Mack, Thomas M. , Matsuno, Rayna K., McCann, Susan E. , Moysich, Kristen B., Pike, Malcolm C. , Shu, Xiao-Ou , Strom, Brian L., Group, The Australian National Endometrial Cancer Study, Ursin, Giske , Webb, Penny M., Weiss, Noel S. , Wentzensen, Nicolas , Setiawan, Veronica Wendy , Bernstein, Leslie , Cai, Hui , Cerhan, James R. , Cozen, Wendy , Doherty, Jennifer A. , Freudenheim, Jo L. , Goodman, Marc T. , Rebbeck, Timothy R. , Robien, Kim , Shu, Xiao-Ou , Spurdle, Amanda B. , Group, The Australian National Endometrial Cancer Study, Xiang, Yong‐Bing , Webb, Penny M., Yang, Hannah , Vivo, Immaculata De , Lissowska, Jolanta

Mayo Clinic

Cancer Research | July 21, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 1900-1900

10.1158/1538-7445.am2011-1900 Get It

Abstract Some studies show that childbearing at older age is associated with lower risk of endometrial cancer, but whether the association is independent of number of children or other factors still requires clarification. We pooled individual-level data from epidemiologic studies in the Epidemiology of Endometrial Cancer Consortium (E2C2). Data on age at last birth and/or last pregnancy were available from 14 studies: 11 case-control studies and 3 cohort studies; the latter were analyzed using a nested case-control design. A total of 9,613 endometrial cancer cases and 17,112 controls were included in the analysis. The majority of women were White (82%) and older than 55 years (69%). We estimated the effects of age at last birth using data from 12 studies and age at last pregnancy using data from 10 studies on the risk of endometrial cancer by calculating odds ratios (OR) and 95% confidence intervals (95% CI) using logistic regression models. Potential confounders included in the analysis were race, body mass index, parity, age at menarche, age at first birth, oral contraceptive use, postmenopausal hormone use, smoking status, and report of diabetes. After adjusting for potential confounders, a reduction in endometrial cancer risk was observed in women with increasing age at last birth (P trend <0.0001) and age at last pregnancy (P trend <0.0001). The OR per five-year increase in age at last birth and age at last pregnancy was 0.90 (95%CI: 0.86, 0.94) and 0.91 (95% CI: 0.87, 0.95), respectively. Women who had their last child at an age >40 years were at a 34% decreased risk compared with women who had their last child at an age <25 years (95% CI: 0.52, 0.82). Compared to women with age at last pregnancy <25 years, those with age at last pregnancy >40 years had a 30% decreased risk of endometrial cancer (95%CI: 0.57, 0.86). Inverse associations were observed for Whites and Asians in race-specific analysis and also in analysis restricted to women with at least 2 births. In this large pooled analysis, we show that late age at last birth or last pregnancy is a strong and independent protective factor for endometrial cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1900. doi:10.1158/1538-7445.AM2011-1900
P3‐027: Pioglitazone decreases phosphorylated and total tau protein
Shirafuji, Norimichi, Ishida, Chiemi, Yen, Shu‐Hui, Ueno, Asako , Yoneda, Makoto , Nakamoto, Yasunari , Kuriyama, Masaru, Hamano, Tadanori

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_13 | Pages: No page available

10.1016/j.jalz.2012.05.1245 Get It

Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension
Hinderliter, Alan L. , Willis, Park W., Barst, Robyn J., Rich, Stuart , Rubin, Lewis J. , Badesch, David B., Groves, Bertron Μ., McGoon, Michael D., Tapson, Victor F. , Bourge, Robert C. , Brundage, Bruce H., Koerner, Spencer K., Langleben, David , Keller, Cesar A., Murali, Srinivas, Koch, Gary G., Clayton, Linda, Jöbsis, Maria M., Blackburn, Shelmer D., Crow, James W., Long, Walker, Uretsky, Barry F. , Li, Shu

Mayo Clinic

Circulation | June 12, 2012 | Volume: 95 | Issue: 6 | Pages: 1479-1486

10.1161/01.cir.95.6.1479 | PMID 9118516 Get It

BackgroundRight heart failure is an important cause of morbidity and mortality in primary pulmonary hypertension. In a recent prospective, randomized study of severely symptomatic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, quality of life, and survival. This article describes the echocardiographic characteristics of participants in this trial; the relationships of echocardiographic variables to hemodynamic parameters, exercise capacity, and quality of life; and the echocardiographic changes associated with prostacyclin therapy.Methods and ResultsThe 81 patients enrolled in this multicenter trial were randomized to treatment with a long-term infusion of prostacyclin in addition to conventional therapy (n=41) or conventional therapy alone (n=40) for 12 weeks. Echocardiograms and assessments of hemodynamics, exercise capacity, and quality of life were performed before and after the treatment phase. On baseline evaluation, patients had marked right ventricular dilatation and dysfunction, abnormal septal curvature, and significant tricuspid regurgitation with a high regurgitant velocity. Pericardial effusions were common. More pronounced abnormalities in right heart structure and function were associated with higher pulmonary arterial and mean right atrial pressures, lower cardiac index, and impaired exercise capacity but had no predictable relationship to quality-of-life indicators. The 12-week infusion of prostacyclin had beneficial effects on right ventricular size, curvature of the interventricular septum, and maximal tricuspid regurgitant jet velocity.ConclusionsThe echocardiographic manifestations of severe primary pulmonary hypertension reflect abnormalities in hemodynamics and exercise capacity. Prostacyclin has beneficial effects on right heart structure and function that may contribute to the clinical improvement and prolonged survival observed with this drug.
Impact of Acute Pulmonary Rejection on Cardiac Function
McLarty, Allison J., McGregor, Christopher G.A. , Shu, Nai H., Miller, Virginia M. , Ritman, Erik L.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 91 | Issue: 1 | Pages: 186-191

10.1161/01.cir.91.1.186 | PMID 7805201 Get It

Background Experiments were designed to define cardiac function in dogs with single lung allografts during acute rejection of the allografted lung. Methods and Results Left lungs were either autotransplanted (n=4) or allotransplanted (n=8) in adult male mongrel dogs. All allotransplanted animals were maintained on triple-drug immunosuppression (cyclosporine, azathioprine, and steroids) for 5 days after the operation. In 4 allotransplanted animals, treatment was discontinued, allowing the animals to reject (usually after a further 3 days; rejecting group); 4 other allotransplanted animals were maintained on immunosuppression for an additional 3 days (immunosuppressed group). Another group of dogs were not operated on but were maintained on the same immunosuppression as the rejecting group (controls). All experimental animals underwent fast computed tomographic scanning with measurement of left ventricular pressure and calculation of ventricular chamber volumes, cross-sectional areas of coronary arteries, myocardial perfusion, and intramyocardial blood volume. Neither cardiac output, left ventricular mass, left ventricular pressure, nor myocardial oxygen consumption was altered during acute rejection of lung allografts. However, left ventricular contractility (systolic elastance, E max ) and ejection fraction were depressed to approximately one half ( P <.05) in acutely rejecting animals compared with other groups. The cross-sectional area of the coronary arteries was less in autotransplanted and allotransplanted treated animals than in animals that were not operated on. Cross-sectional area of the coronary arteries was decreased by an additional 30% in the rejecting group ( P <.05). Conclusions The results of this study indicate that acute rejection of a single lung allograft decreases cardiac performance and reduces diameter of coronary arteries in the recipient. Alterations of circulating humoral factors and activated leukocytes may contribute to these changes.
Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Pasquinelli, C, McPhee, Fiona, Eley, Timothy, Villegas, Criselda, Sandy, Katrina, Sheridan, Pamela L., Persson, Anna , Huang, Shu-Pang, Hernandez, Dennis , Sheaffer, Amy K. , Scola, Paul M. , Marbury, Thomas , Goldwater, Ronald, Rodríguez‐Torres, M., DeMicco, Michael, Wright, David W. , Kraft, Walter K. , Lopez-Talavera, Juan-Carlos, Grasela, Dennis M., Lawitz, Eric , Charlton, Michael

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 31, 2012 | Volume: 56 | Issue: 4 | Pages: 1838-1844

10.1128/aac.05854-11 | PMID 22290978 Get It

ABSTRACT Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.
P3‐209: Pitavastatin decreases tau levels via the inactivation of Rho family small G proteins
Yen, Shu‐Hui, Ko, Li‐wen, Shirafuji, Norimichi, Yoneda, Makoto , Kuriyama, Masaru, Hamano, Tadanori , Gendron, Tania F.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2011.05.1650 Get It

Label-Free Proteomic Identification of Endogenous, Insulin-Stimulated Interaction Partners of Insulin Receptor Substrate-1
Geetha, Thangiah , Langlais, Paul R. , Luo, Moulun , Mapes, Rebekka, Lefort, Natalie , Mandarino, Lawrence J. , Yi, Zhengping , Chen, Shu‐Chuan , Geetha, Thangiah

Mayo Clinic

Journal of the American Society for Mass Spectrometry | January 28, 2011 | Volume: 22 | Issue: 3 | Pages: 457-466

10.1007/s13361-010-0051-2 | PMID 21472564 Get It

P1‐371: Characteristics of cytosolic hyperphosphorylated tau species in rTg4510 mouse brain
DeTure, Michael , Ebrahim, Abdul-Shukkur, Christensen, S⊘ren, Kang, Dongcheul, Knight, Josh , Petrucelli, Leonard , Yen, Shu‐Hui, Lewis, Jada , Sahara, Naruhiko , Volbracht, Christiane

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2010.05.925 Get It